Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001650 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of the PfSPZ Vaccine
A Phase 1 study of Plasmodium Falciparum, sponsored by Sanaria.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT01001650 is a Phase 1 study of Plasmodium Falciparum that has completed, run by Sanaria. The registered enrollment target is 80 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT01001650, a Phase 1 study of Plasmodium Falciparum, has completed, sponsored by Sanaria.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose subcutaneous (SC) or intradermal (ID) administration. In addition, the investigators wish to evaluate PfSPZ vaccine-mediated protection against P. falciparum challenge in the following 4 groups (see below) and compare protective efficacy of the PfSPZ vaccine when given by SC v ID administration in all these groups: * Group 1: 4 doses of 7,500 PfSPZ/immunization, * Group 2: 4 doses of 30,000 PfSPZ/immunization, * Group 3: 4 doses of 135,000 PfSPZ/immunization * Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization. If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
Conditions Studied
Interventions
- BIOLOGICAL Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Study Locations (2)
Maryland
- The Center for Vaccine Development, University of Maryland (CVD/UMB) - Baltimore
- Naval Medical Research Center (NMRC) Clinical Trials Center, on the campus of the National Naval Medical Center (NNMC) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001650
The ClinicalTrials.gov registry entry for NCT01001650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanaria, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasmodium Falciparum appearing as the primary indexed condition, and to 1 intervention - of which Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation) is the first listed.
NCT01001650 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01001650 about?
NCT01001650 is a clinical study titled "Clinical Trial of the PfSPZ Vaccine". The purpose of this study is to determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose subcutaneous (SC) or intradermal (ID) administration. In addition, the invest...
What is the current status of trial NCT01001650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2009-04. Estimated completion is 2010-09.
What conditions does trial NCT01001650 study?
This clinical trial studies the following conditions: Plasmodium Falciparum.
What interventions are being tested in trial NCT01001650?
The interventions under investigation include: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01001650?
This trial is sponsored by Sanaria, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01001650 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasmodium Falciparum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.